Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal versus intramuscular Comirnaty booster dosing in adults aged 75 years and older
NL-OMON60114Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Radboud University Medical Center. Primary endpoint: Anti-S IgG geometric mean concentration at day 28. Started Sep 2023; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON60114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60114.